Total raised
$42.5M
Last: Series B 2024-10
Stage
Series B
Founded
2016
Headcount
22
HQ
Sector
Health Tech & Life Sciences
About
Innoventric is a structural heart medical device company engaged primarily in the development of percutaneous solutions for tricuspid regurgitation and right heart disease. The company has developed an easily deployable percutaneous functional tricuspid valve replacement that utilizes cross-caval anchoring and an innovative multi-valve design for long-lasting blood flow regulation. Innoventric is dedicated to the development of simple yet sophisticated transcatheter solutions to significantly improve the quality of life and life span of patients with structural heart disease.
Funding history · 3 rounds · $42.5M total
2024-10
Series B
$28.5M
2021-11
Series A
$11.0M
2017-08
Seed
Undisclosed
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Highlights
1 Patents
Tags
valveshealthcare-providersmedical-devicescardiovascular